# Non-alcoholic Fatty Liver Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/non-alcoholic-fatty-liver-disease

> 6 upcoming FDA catalysts in non-alcoholic Fatty Liver Disease: Rezdiffra (resmetirom, MDGL) on March 2027 (primary completion); Rezdiffra (resmetirom, MDGL) on Mar to Jun 2027 (topline data readout); efimosfermin alfa (GSK) on Mar to Jun 2028 (topline data readout); efimosfermin alfa (GSK) on Mar to Jun 2028 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 23, 2025 | [GSK4532990 primary completion](https://sec-api.dev/pdufa/gsk4532990) | GSK | Non-alcoholic Fatty Liver Disease | completed | "NCT06104319 (Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06104319)) |
| October 27, 2026 | [GSK4532990 topline data readout](https://sec-api.dev/pdufa/gsk4532990) | GSK | Non-alcoholic Fatty Liver Disease | completed | "NCT06104319 (Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06104319?tab=results)) |
| March 2027 | [Rezdiffra (resmetirom) primary completion](https://sec-api.dev/pdufa/resmetirom) | MDGL | Non-Alcoholic Fatty Liver Disease | scheduled | "NCT04951219 (A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04951219)) |
| Mar to Jun 2027 | [Rezdiffra (resmetirom) topline data readout](https://sec-api.dev/pdufa/resmetirom) | MDGL | Non-Alcoholic Fatty Liver Disease | scheduled | "NCT04951219 (A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04951219)) |
| Mar to Jun 2028 | [Efimosfermin alfa topline data readout](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Non-alcoholic Fatty Liver Disease | scheduled | "NCT07221188 (A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221188)) |
| Mar to Jun 2028 | [Efimosfermin alfa topline data readout](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Non-alcoholic Fatty Liver Disease | scheduled | "NCT07221227 (A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221227)) |
| March 2028 | [Efimosfermin alfa primary completion](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Non-alcoholic Fatty Liver Disease | scheduled | "NCT07221188 (A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221188)) |
| March 2028 | [Efimosfermin alfa primary completion](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Non-alcoholic Fatty Liver Disease | scheduled | "NCT07221227 (A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221227)) |

## Drugs

- [GSK4532990](https://sec-api.dev/pdufa/gsk4532990) (GSK)
- [Rezdiffra (resmetirom)](https://sec-api.dev/pdufa/resmetirom) (MDGL)
- [Efimosfermin alfa](https://sec-api.dev/pdufa/efimosfermin-alfa) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/non-alcoholic-fatty-liver-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Non-alcoholic Fatty Liver Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/non-alcoholic-fatty-liver-disease

```bibtex
@misc{secapidev_indications_non_alcoholic_fatty_liver_disease_20261116,
  title        = {Non-alcoholic Fatty Liver Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/non-alcoholic-fatty-liver-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_non_alcoholic_fatty_liver_disease_20261116","title":"Non-alcoholic Fatty Liver Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/non-alcoholic-fatty-liver-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
